Intravenous immunoglobulin-associated vena cava thrombosis

• References

• 1 Shoenfeld Y. Fifth international symposium on IvIg: IvIg in the third millenium, 25–27 September 2003, Interlaken, Switzerland: a meeting review. Autoimmun Rev 2004; 03: 234-41.
• 2 Shoenfeld Y, Katz U. IvIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005; 38: 123-37.
• 3 Achiron A. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1997; 49: 899-900.
• 4 Alexandrescu DT, Dutcher JP, Hughes JT. et al. Strokes after intravenous gamma globulin: Thrombotic phenomenon in patients with risk factors or just coincidence?. Am J Hematol 2005; 78: 216-20.
• 5 Butler KS, Zeitlin DS. Pulmonary embolism associated with intravenous immunoglobulin therapy. Ann Pharmacother 2003; 379: 1530.
• 6 Caress JB, Cartwright MS, Donofrio PD. et al. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003; 60: 1822-4.
• 7 Crouch ED, Watson LE. Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura- a case report and literature review. Angiology 2002; 53: 113-7.
• 8 Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology 1994; 44: 223-6.
• 9 Dalakas M, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 2003; 60: 1736-7.
• 10 Elkayam O, Paran D, Milo R. et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 2000; 59: 77-80.
• 11 Emerson GG, Herndon CN, Streih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy 2002; 22: 1638-41.
• 12 Evangelou N, Littlewood T, Anslow P. et al. Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol 2003; 56: 308-9.
• 13 Feuillet L, Guedj E, Laskiri N. et al. Deep venous thrombosis after intravenous immunoglobulins associated with methylprednisolone. Thromb Haemost 2004; 92: 662-5.
• 14 Frame WD, Crawford RJ. Thrombotic events after intravenous immunoglobulin. Lancet 1986; 02: 468.
• 15 Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients:a case report and discussion of the relevant literature. Ann Hematol 2004; 83: 661-5.
• 16 Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglo-bulin-related thrombotic complications. Mayo Clin Proc 2000; 75: 83-5.
• 17 Okuda D, Flaster M, Frey J. et al. Arterial thrombosis induced by IvIg and its treatment with tPA. Neurology 2003; 60: 1825-6.
• 18 Stangel M, Kiefer R, Pette M. et al. Side effects of intravenous immunoglobulins in neurological autoimmune disorders. A prospective study. J Neurol 2003; 250: 818-21.
• 19 Katz U, Shoenfeld Y. Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 2005; 14: 802-8.
• 20 Marie I, Hervé F, Lahaxe L. et al. Intravenous immunoglobulin-associated cranial pachymeningitis. J Intern Med 2006; 260: 164-7.
• 21 Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney-A two-edged sword. Semin Arthritis Rheum 2004; 34: 593-601.
• 22 Sherer Y, Levy Y, Langevitz P. et al. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001; 62: 133-7.
• 23 Zaidan R, Al Moallem M, Wani BA. et al. Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol 2003; 10: 367-72.
• 24 Harkness KA, Goulding P. Central retinal vein occlusion complicating treatment with intravenous immunoglobulin. Eye 2000; 14: 662-3.
• 25 Hommes OR, Sorensen PS, Fazekas F. et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364: 1149-56.
• 26 Katz KA, Hivnor CM, Geist DE. et al. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 2003; 139: 991-3.
• 27 Oh KT, Boldt HC, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophtalmol 1997; 124: 416-8.
• 28 Paran D, Herishanu Y, Elkayam O. et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005; 16: 313-8.
• 29 Stolz E, Klötzsch C, Schlachetzki F. et al. Highdose corticosteroid treatment is associated with an increased risk of developing cerebral venous thrombosis. Eur Neurol 2003; 49: 247-8.
• 30 Vucic S, Chong PS, Dawson KT. et al. Thromboembolic complications of intravenous immunoglobulin treatment. Eur Neurol 2004; 52: 141-4.
• 31 Ben-Ami R, Barshtein G, Mardi T. et al. A synergistic effect of albumin and fibrinogen on immunoglobulin-induced red blood cell aggregation. Am J Physiol Heart Circ Physiol 2003; 285: H2663-H2669.
• 32 Grillo JA, Gorson KS, Ropper AH. et al. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology 2001; 57: 1699-701.
• 33 Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 339: 662-4.
• 34 Steinberger BA, Ford SM, Coleman TA. Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. Am J Hematol 2003; 73: 97-100.
• 35 Marie I, Maurey G, Hervé F. et al. Intravenous immunoglobulin-associated arterial and venous thrombosis: report of a series and review of the literature. Br J Dermatol 2006; 155: 714-21.